“…Since the American Diabetes Association endorsed HBOT for treating recalcitrant diabetic foot ulcers in 1999, it has been widely used and explored for treating chronic wounds [ 6 , 46 ]. According to several clinical and experimental studies, HBOT can promote the healing of chronic wounds to a certain extent by various mechanisms, such as enhancing the local pO 2 , reducing the inflammatory response, promoting the secretion of VEGF to enhance angiogenesis, and mobilizing bone marrow mesenchymal stem cells to migrate to the wound area [ [47] , [48] , [49] , [50] ]. However, it is worth noting that tissue reoxygenation via HBOT depends on the functioning vascular system.…”